



August 8, 2024

## Notice Regarding the Revision of the Consolidated Financial Forecast for the Fiscal Year Ending March 31, 2025

This is to announce that the consolidated financial forecast for the fiscal year ending March 31, 2025 announced on May 9, 2024 is revised as below.

### 1. Revision of the Consolidated Financial Forecast

#### (1) Consolidated Financial Forecast for the First Half of the Year ending September 30, 2024

(From April 1, 2024 to September 30, 2024)

	Revenue	Operating Profit	Profit before Tax	Profit Attributable to Owners of Parent	Basic Earnings per Share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecast (A)	350,000	11,000	14,000	10,000	28.86
Revised Forecast (B)	346,000	7,000	10,000	7,000	20.20
Difference (B-A)	(4,000)	(4,000)	(4,000)	(3,000)	
Change (%)	(1.1)%	(36.4)%	(28.6)%	(30.0)%	
(Reference) Results of the First Half ended September 30, 2023	331,296	13,629	15,260	9,801	28.30

#### (2) Consolidated Financial Forecast for the Year ending March 31, 2025 (From April 1, 2024 to March 31, 2025)

	Revenue	Operating Profit	Profit before Tax	Profit Attributable to Owners of Parent	Basic Earnings per Share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecast (A)	745,000	35,000	40,000	30,000	86.59
Revised Forecast (B)	750,000	35,000	40,000	30,000	86.59
Difference (B-A)	5,000	–	–	–	
Change (%)	0.7%	–	–	–	
(Reference) Results of the Year ended March 31, 2024	717,245	39,776	42,669	32,570	94.03

### 2. Background of the Revision of Consolidated Financial Forecast

We made downward revision as above 1.(1) to the consolidated financial forecast for the first half of the year ending September 30, 2024, reflecting sales deferred from the first half to the second half of this fiscal year in the semiconductor lithography system field of the Precision Equipment Business and in the Components Business, as well as the consolidated financial results for the three months ended June 30, 2024 and sales deferred from the first half to the second half in the Healthcare Business, despite continued strong performance of the Imaging Products Business. On the other hand, we made upward revision as above 1.(2) to the consolidated financial forecast for the year ending March 31, 2025 mainly in light of the consolidated financial results for the three months ended June 30, 2024, including positive effects of the yen depreciation in the Imaging Products Business.

The above forecast is based on the assumption of foreign exchange rates from the second quarter onward of 1 USD = ¥145 and 1 EUR = ¥155, as was the case with the previous announcement.

Forecast in this disclosure is made by management in light of information currently available. A number of factors could cause actual results to differ materially from those disclosed as above.

End of document